FDA approves Moderna's mRNA seasonal flu vaccine

Quick Summary

The FDA has approved Moderna's mRNA seasonal flu vaccine, marking a significant milestone in the development of mRNA vaccines for seasonal flu. This vaccine uses the same mRNA technology as Moderna's COVID-19 vaccine and is expected to provide protection against multiple strains of the flu virus. The approval is a major step forward in the fight against seasonal flu, which can cause severe illness and death, especially among vulnerable populations such as the elderly and young children.

Key Points